Any current/future new fundraising through debt or equity?

There is no indication of any new fundraising through debt or equity in the call. The company plans capex of around INR 600 crores for FY25, primarily for Granules Life Sciences expansion and other projects. Net debt as of year-end is INR 842 crores, with a targeted net debt-to-EBITDA ratio of around 1 to 1.1, which the company aims to maintain rather than drastically reduce. No plans to bring net debt down drastically; small fluctuations plus or minus may occur. The company intends to maintain healthy net debt levels and is cautious about taking on more debt to keep the ratio within target. I

Any current/future capex/capital investment/strategic investment?

FY25 Capex estimated at INR 600 crores (INR 6,000 million). Half of the capex allocated to Granules Life Sciences expansion; remaining for other projects and maintenance. New formulation facility at Genome Valley (Granules Life Sciences) commenced operations in March 2024 with ramp-up expected to reach 100 million dosages per month by July-August 2024. Granules Life Sciences capacity expected to generate INR 4-5 billion revenue in FY25. Cautious approach to CZRO investment; spending aligned with project milestones ("state gate" approvals). Commercial scale-up planned for the DCDA pilot plant a

Future growth expectations in sales/revenue/volumes?

Finished Dosage (FD) segment will be the main driver of future growth with healthy, possibly better than last year's growth. New product launches, including CNS, ADHD, MUPS, and first-to-file launches, will significantly contribute to revenue growth starting FY25 and more markedly in FY26. Value-added products expected to increase from 65% to around 70% of sales by next year, enhancing margins and revenue quality. Formulation capacity ramp-up at Genome Valley expected to touch annualized revenue capacity of INR 4-5 billion by FY25. New products anticipated to contribute 7-10% to FY25 r

Future growth expectations in earnings/operating earnings/profits/EPS?

Finished Dosage (FD) segment expected to drive strong growth, possibly better than FY24's >25% growth. EBITDA margin targeted around 22%-23%, with potential to maintain or improve; conservative outlook given. Gross margins expected to sustain between 55%-58% driven by higher FD sales and favorable raw material costs. New product launches anticipated to contribute 7%-10% of revenues in FY25, with growth in new products accelerating in subsequent years. Capex of around INR600 crores planned in FY25 for expansions and maintenance, supporting future growth. Demand environment broadly buo

Current/ Expected Orderbook/ Pending Orders?

Granules India Limited, combining both GPI and GIL entities, currently has around 13 ANDAs (Abbreviated New Drug Applications) pending approval. The company has a strong pipeline with many first-to-file launches, including oncology and other specialized areas. They anticipate continuing R&D spend to support this pipeline and product development. The company expects approximately 16 to 18 product launches in the fiscal year, of which 14 are new products and the rest product extensions/ramp-ups. New product approvals, especially in CNS, ADHD, and MUPS categories, are expected to contribu

IN US

Sale is live|00:00:00left today

Granules India LtdQ1 FY24Pharmaceuticals & Biotechnology

Granules India Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹776P/E: 30.3Market Cap: ₹18.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Finished Dosage (FD) segment will be the main driver of future growth with healthy, possibly better than last year's growth.
→New product launches, including CNS, ADHD, MUPS, and first-to-file launches, will significantly contribute to revenue growth starting FY25 and more markedly in FY26.
→Value-added products expected to increase from 65% to around 70% of sales by next year, enhancing margins and revenue quality.
→Formulation capacity ramp-up at Genome Valley expected to touch annualized revenue capacity of INR 4-5 billion by FY25.
→New products anticipated to contribute 7-10% to FY25 revenues, with growth accelerating in subsequent years.
→Market expansion, including increasing presence in U.S., Europe, and other regulated markets, supports volume and sales growth.
→Despite challenges in Paracetamol API segment, stabilization expected from FY26 and overall good demand environment for most products.

Margin guidance

Category 3

→Finished Dosage (FD) segment expected to drive strong growth, possibly better than FY24's >25% growth.
→EBITDA margin targeted around 22%-23%, with potential to maintain or improve; conservative outlook given.
→Gross margins expected to sustain between 55%-58% driven by higher FD sales and favorable raw material costs.
→New product launches anticipated to contribute 7%-10% of revenues in FY25, with growth in new products accelerating in subsequent years.
→Capex of around INR600 crores planned in FY25 for expansions and maintenance, supporting future growth.
→Demand environment broadly buoyant except paracetamol API, where stabilization expected by FY26.
→R&D spends to continue or slightly increase due to strong pipeline, focusing on first-to-file and specialty segments like oncology.
→Operating leverage expected as current higher costs (manpower, R&D) normalize with scaling revenues.
→Net debt target maintained at a comfortable net debt to EBITDA ratio of 1.0-1.1.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no indication of any new fundraising through debt or equity in the call.
→The company plans capex of around INR 600 crores for FY25, primarily for Granules Life Sciences expansion and other projects.
→Net debt as of year-end is INR 842 crores, with a targeted net debt-to-EBITDA ratio of around 1 to 1.1, which the company aims to maintain rather than drastically reduce.
→No plans to bring net debt down drastically; small fluctuations plus or minus may occur.
→The company intends to maintain healthy net debt levels and is cautious about taking on more debt to keep the ratio within target.
→Interest costs are expected to remain steady in the near term due to Fed rates.
→Overall, no new fundraising announcements or plans were shared in the discussion.

Order book

→Granules India Limited, combining both GPI and GIL entities, currently has around 13 ANDAs (Abbreviated New Drug Applications) pending approval.
→The company has a strong pipeline with many first-to-file launches, including oncology and other specialized areas.
→They anticipate continuing R&D spend to support this pipeline and product development.
→The company expects approximately 16 to 18 product launches in the fiscal year, of which 14 are new products and the rest product extensions/ramp-ups.
→New product approvals, especially in CNS, ADHD, and MUPS categories, are expected to contribute significantly but not heavily from Q1 FY25.
→Commercialization of oncology and other innovative products is planned to begin from FY26 onwards.
→Capex of about INR 600 crores is planned for FY25, supporting expansion and other projects to meet order demands.

Capex plans

Yes

→FY25 Capex estimated at INR 600 crores (INR 6,000 million).
→Half of the capex allocated to Granules Life Sciences expansion; remaining for other projects and maintenance.
→New formulation facility at Genome Valley (Granules Life Sciences) commenced operations in March 2024 with ramp-up expected to reach 100 million dosages per month by July-August 2024.
→Granules Life Sciences capacity expected to generate INR 4-5 billion revenue in FY25.
→Cautious approach to CZRO investment; spending aligned with project milestones ("state gate" approvals).
→Commercial scale-up planned for the DCDA pilot plant at Kakinada following successful pilot operations in March 2024.
→Strategic capex focused on backward integration of paracetamol and metformin in a sustainable manner (green pharma initiative).
→Emphasis on expanding manufacturing technology platform and validation of new molecules by Q3 FY25 to achieve cost leadership and sustainability.

How does Granules India Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Granules India Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Granules India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio